Form 8-K · Current Report · Filed 2025-01-31
Revvity Announces Fourth Quarter and Full Year 2024 Financial Results and 2025 Guidance
Revvity, Inc. reported its financial results for Q4 and full-year 2024, announcing Q4 revenue of $729 million with 5% reported growth and 6% organic growth. The company reported GAAP EPS of $0.78 and adjusted EPS from continuing operations of $1.42. For full-year 2024, Revvity reported GAAP EPS of $2.20 and adjusted EPS of $4.90. The company also initiated full-year 2025 guidance, forecasting total revenue of $2.80-$2.85 billion and adjusted earnings per share of $4.90-$5.00. The financial results and guidance include adjustments for non-GAAP measures as detailed in the exhibit.
- Filer
- Revvity Inc. RVTY · NYSE
- Filed
- Accession
- 0000031791-25-000006
- CIK
- 0000031791
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$126.84
Next session
-2.5%
Since filing
+15.7%
Latest close
$146.73
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from RVTY reporting the same item, with the next session's move:
Exhibits (1)
About Revvity Inc.
Revvity Inc. is a global life sciences and diagnostics company that provides health science solutions, technologies, and services for research, development, and clinical testing. Revvity’s current business is organized around two main segments: Life Sciences, which supplies reagents, instruments, and software to support biopharma and academic research; and Diagnostics, which offers assay platforms, instruments, and software for reproductive health, immunodiagnostics, newborn screening, applied genomics, and infectious disease testing. The company also focuses on translational multi-omics, biomarker identification, imaging, screening, detection, and informatics, helping customers move biological data through connected laboratory workflows. Revvity serves pharmaceutical and biotechnology companies, diagnostic laboratories, academic institutions, and government organizations across global markets. Headquartered in Waltham, Massachusetts, Revvity plays an important role in enabling scientific discovery and supporting clinical decision-making across the healthcare and research ecosystem.
Never miss another RVTY filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.